• Inducing Mammalian Embryonic Dormancy via mTOR Inhibition Pr

  2026-07-30

  This article reviews a protocol that enables reversible induction of a diapause-like dormant state in mammalian embryonic cells using pharmacological mTOR inhibition. The approach offers a noninvasive, scalable alternative to traditional surgical methods, facilitating investigation of dormancy mechanisms and potential advances in developmental biology and reproductive technology.

• CLCC1 Enables Membrane Fusion in Herpesvirus Nuclear Egress

  2026-07-30

  A recent study identifies the host chloride channel CLCC1 as an essential mediator of membrane fusion during herpesvirus nuclear egress, a critical step for viral maturation. These findings clarify a longstanding gap in herpesvirus biology and suggest new avenues for antiviral research.

• Cyclic di-GMP: Mastering Biofilm and Immune Modulation Workf

  2026-07-29

  Cyclic di-GMP is redefining research precision in both bacterial biofilm regulation and STING-driven immune modulation. This guide delivers actionable experimental strategies, troubleshooting insights, and evidence-based protocol enhancements, anchored by the latest mechanistic discoveries.

• 17-AAG (Tanespimycin): Optimizing HSP90 Inhibition Workflows

  2026-07-29

  Harness the precision of 17-AAG (Tanespimycin) for reliable HSP90 chaperone inhibition in cancer research. This article provides actionable protocols, advanced troubleshooting, and cross-domain insights for maximizing experimental success with APExBIO’s trusted reagent.

• Lenalidomide (CC-5013): Translational Strategies in Myeloma

  2026-07-28

  This thought-leadership article examines the evolving role of Lenalidomide (CC-5013) as an immune system activation agent and angiogenesis inhibitor in multiple myeloma research. Integrating mechanistic insights, recent epigenetic findings, and workflow guidance, the piece offers translational researchers a roadmap for maximizing therapeutic impact and experimental reproducibility, while contextualizing APExBIO’s product in the landscape of next-generation immuno-oncology.

• Tumor-Targeted PAD4 Inhibitors Disrupt NETs to Suppress Meta

  2026-07-28

  The referenced study introduces meta-phenylboronic acid (m-PBA)-modified PAD4 inhibitors, exemplified by Compound 5i TFA, achieving highly selective tumor targeting and potent inhibition of the PAD4–H3cit–NETs pathway in neutrophils. This approach demonstrates significant antitumor efficacy and precise modulation of the tumor immune microenvironment, providing a new paradigm for selective cancer therapy.

• Epacadostat (INCB024360): Applied Protocols for IDO1 Inhibit

  2026-07-27

  Epacadostat (INCB024360) is redefining preclinical immuno-oncology workflows by enabling precise, nanomolar-scale inhibition of IDO1-driven immune suppression. This guide details evidence-backed workflows, troubleshooting strategies, and the latest advances in whole-blood immunometabolic assays for robust, reproducible investigation.

• Cepharanthine: Bridging Apoptosis Research and Endometriosis

  2026-07-27

  Cepharanthine, a biscoclaurine alkaloid, is rapidly emerging as a focal molecule in both mechanistic and translational research for chronic gynecological diseases. This article unpacks its dual role as an apoptosis inducer and immunomodulatory agent, synthesizing new evidence from organoid and in vivo models of endometriosis. We provide practical guidance for experimental design, compare Cepharanthine to current standards, and chart a forward-looking roadmap for researchers seeking high-efficacy, low-toxicity therapeutic options.

• Pomalidomide (CC-4047) in Hematological Malignancy Research

  2026-07-26

  Pomalidomide (CC-4047) stands out as a precision tool for dissecting tumor microenvironment dynamics and drug resistance in multiple myeloma models. This article translates recent mutational landscape insights into actionable workflows, protocol optimizations, and troubleshooting strategies for applied hematological malignancy research.

• Ferritin Hybrid Protein Particle Vaccine: Influenza A & SARS

  2026-07-25

  This study presents a ferritin-based hybrid protein particle vaccine combining the M2e antigen of influenza A with tandem S protein epitopes from SARS-CoV-2. The approach demonstrates enhanced immunogenicity and protective potential, offering a promising platform for next-generation combination vaccines.

• Redefining In Vitro Drug Response Metrics in Cancer Research

  2026-07-24

  Schwartz (2022) introduces a paradigm-shifting in vitro methodology for evaluating anti-cancer drug responses, distinguishing between proliferative arrest and cell death. This nuanced approach enhances preclinical assay interpretation, shaping how angiogenesis inhibitors like Cediranib (AZD2171) are assessed in cancer research.

• Entinostat (MS-275): Mechanistic Insight for Translational O

  2026-07-24

  Explore how Entinostat (MS-275) reshapes translational cancer research by bridging advanced mechanistic understanding with actionable guidance for in vitro and in vivo workflows. This article highlights Entinostat's selective HDAC1/3 inhibition, the nuanced evaluation of anti-cancer drug effects, and strategic considerations for researchers aiming to optimize epigenetic therapies.

• Cyclic di-GMP: Bridging Bacterial Persistence and Immune Mod

  2026-07-23

  Discover how cyclic di-GMP, a key intracellular second messenger, orchestrates both bacterial biofilm resilience and immune modulation. This article uniquely explores the mechanistic cross-talk between microbial persistence and STING-driven immunity, offering actionable insights for advanced research.

• Targeting Hippocampal CA2: AAV/M1-Cre as a Precise Research

  2026-07-23

  Peng et al. introduce a novel AAV/M1-Cre vector leveraging the mini Map3k15 promoter for highly specific labeling and manipulation of hippocampal CA2 neurons in mice. This advancement addresses a longstanding technical bottleneck, enabling finer dissection of CA2's roles in memory and social cognition.

• Radicicol: Mechanistic Insights for Precision Adipogenesis a

  2026-07-22

  Explore the multifaceted role of Radicicol as a potent Hsp90 inhibitor, delving into its molecular mechanisms and unique applications in adipogenesis and inflammation research. This article offers a distinct, in-depth analysis that advances beyond standard protocols.

16579 records 1/1106 page Next 12345 下5页 Last page